节点文献
超小剂量地西他滨联合半疗程CAG 治疗老年高危骨髓增生异常综合征的临床观察
Analysis of ultra low dose decitabine combined with half quantity of CAG regimen in treatment of elderly high-risk myelodysplastic syndrome
【摘要】 目的:探讨超小剂量地西他滨(DAC)联合半疗程CAG方案治疗老年高危MDS的疗效和安全性。方法:回顾性分析48例老年高危MDS患者的临床资料,按接受不同治疗方案分为超小剂量DAC联合半疗程CAG方案的观察组(26例)和接受DAC单药治疗的对照组(22例),观察2组的疗效、安全性与生存时间。结果:观察组与对照组比较,完全缓解率及总缓解率差异虽无统计学意义,但是1年累积总生存率和2年累积总生存率均增加(P<0.05);2组患者不良反应发生率比较,观察组优于对照组,差异有统计学意义(P<0.05)。结论:超小剂量DAC联合半疗程CAG化疗方案治疗骨髓增生异常综合征,患者生存时间长,安全性好
【Abstract】 Objective:To observe the efficacy and safety of ultra low dose of decitabine(DAC) combined with half quantity of CAG regimen in treatment of elderly high-risk myelodysplastic syndrome(MDS).Methods: Clinical data of 48 elderly patients with high-risk MDS were retrospectively analyzed.26 patients receiving ultra-small-dose DAC combined with the half quantity CAG regimen were included as the observation group, and 22 patients treated with DAC monotherapy as the control group. The efficacy, safety and survival time of the two groups were observed.Results: Although there was no significant difference in complete remission rate and total remission rate between the observation group and the control group, the 1-year and 2-year cumulative total survival rates of the observation group increased(P<0.05). The incidence of adverse reaction, including bleeding and infection, of the observation group was lower than that of the control group(P<0.05).Conclusion: Ultra-small-dose DAC combined with half quantity of CAG regimen can be a safe and effective option for the treatment of elderly patients with high-risk MDS.
【Key words】 Myelodysplastic syndrome; Decitabine; CAG regimen; Elderly;
- 【文献出处】 淮海医药 ,Journal of Huaihai Medicine , 编辑部邮箱 ,2019年05期
- 【分类号】R551.3
- 【被引频次】2
- 【下载频次】56